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Abstract High levels of adherence are required to achieve
the full benefit of ART. We assess the effectiveness of
electronic adherence monitoring devices among patients
failing second-line ART, as measured by viral load sup-
pression. Cohort study of WisepillTM real-time adherence
monitoring in addition to intensified adherence counselling
over 3 months in adults with a viral load C400 copies/ml
on second-line ART in Johannesburg, South Africa
between August 2013 and January 2014. Patients were sent
SMS reminders upon missing a scheduled dose. We com-
pared outcomes to earlier historical cohorts receiving
either intensified adherence counselling or adherence
counselling alone. Overall, 63 % of the participants (31/49)
took[80 % of their prescribed medication; this dropped
from 76 to 53 and 49 % at 1, 2 and 3 months post-enrol-
ment respectively. Compared to those with good adherence
([80 %), participants with poor adherence (B80 %) had a
higher risk for a subsequently elevated viral load C400
copies/ml (relative risk (RR) 1.47 95 % CI 0.97–2.23).
Participants found the intervention ‘‘acceptable and useful’’
but by 6 months after eligibility they were only slightly
more likely to be alive, in care and virally suppressed
compared to those who received intensified adherence
counselling (44.9 vs. 38.5 %; RR 1.19; 95 % CI 0.85–1.67)
or adherence counselling alone (44.9 vs. 40.9 %; RR 1.12;
95 % CI 0.81–1.56). In patients with an elevated viral load
on second-line ART electronic adherence monitoring was
associated with a modest, but not significant, improvement
in viral suppression.
Keywords Second-line  Electronic adherence monitoring
device (EAMD)  WisepillTM  Adherence  Viral
suppression
Introduction
The advent of antiretroviral therapy (ART) has led to sig-
nificant reductions in morbidity and mortality [1–3].
Despite the huge successes in increasing HIV treatment
coverage, most patients who experience virologic failure
on second-line ART in low-middle income countries fail
due to poor adherence rather than resistance to a class of
ART drugs [4, 5]. For patients on second-line protease
inhibitor-based ART, high levels (C80 %) of adherence are
required for viral suppression and poorer outcomes are
observed when adherence drops [6, 7].
Some patients demonstrating poor adherence go on to
fail therapy, develop resistance and require more expensive
subsequent treatment regimens [8–12]. In most resource-
limited settings, access to second-line treatment is limited
and access to third-line is non-existent [13]. In South
Africa, second-line treatment is readily available but comes
at a significantly higher cost compared to first-line therapy,
which forces a shift of resources away from initiating new
patients onto treatment [11]. Delaying the need for second-
and third-line therapy through improved treatment
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adherence is of the utmost importance for maximizing
existing resources. The cost of third-line regimens has been
estimated to be more than 15 times that of first-line and six
times that of second-line regimens.
While several interventions to improve adherence exist
[14, 15], most can only identify poor adherence after it has
already become a problem [16]. Some studies report that
50 % of non-adherent patients may experience loss of viral
suppression after a 14 day lapse in adherence [17], there-
fore highlighting the need to identify poor adherence early.
Real-time electronic adherence monitoring devices
(EAMD) have been proposed for improving adherence as it
presents the opportunity to identify missed doses in as little
as 24–48 h. While these devices are often used in clinical
trials of HIV drugs, recent studies have demonstrated that
the data from these devices can be effectively used to
improve patient adherence or reduce treatment interrup-
tions of[72 h in the routine outpatient ART clinic setting
[18, 19]. These real-time, wireless adherence monitoring
strategies for ART may provide novel opportunities to
proactively prevent virologic rebound and treatment failure
[17]. While these devices have been shown to be effective
in first-line patients [16, 17, 19] there are questions as to
whether such a strategy is cost effective. To date, no study
has focused on patients with an elevated viral load on
second-line ART, a population that would be both at high
risk for poor adherence and in whom preventing the need
for very expensive and difficult to access third-line regi-
mens could prove to be cost-effective.
We conducted a pilot study to assess the effectiveness of
EAMD in achieving adherence among adult patients with
an elevated viral load (C400 copies/ml) on second-line
ART. Adherence was defined as achieving a suppressed
viral load (\400 copies/ml) between 3 and 6 months after
an elevated viral load (C400 copies/ml) on second-line
ART. We compare outcomes to two historical cohorts
receiving the standard of care; the one cohort received
intensified adherence counselling while the other received
standard adherence counselling. In addition to generating
preliminary estimates of effectiveness, we generate pre-
liminary cost data and evaluate the feasibility of EAMD.
Methods
Study Site
This study was conducted among HIV-positive adult
(C18 years) patients receiving treatment at the Themba
Lethu Clinic in Johannesburg, South Africa. The Themba
Lethu Clinic (TLC) cohort has been described elsewhere
[20]. Themba Lethu is a large public sector HIV compre-
hensive care, management and treatment (CCMT) site that
follows the national HIV treatment guidelines [21–23].
Patients who fail first-line therapy are switched to a regi-
men containing a protease inhibitor (PI), typically lopina-
vir-ritonavir (LPVr) and two nucleoside reverse
transcriptase inhibitors (NRTI). HIV viral load testing is
used in South Africa to determine when a patient is con-
sidered to have failed an ART regimen.
By January 2014, Themba Lethu had initiated over
22,000 adult patients onto ART and of these 2790 have
initiated second-line therapy. Of the patients that have
initiated second-line ART, close to 20 % received inten-
sified adherence counselling for an elevated viral load
while on second-line ART.
Study Design and Population
We conducted an ambi-directional cohort study comparing
patients in the intervention cohort (EAMD in addition to
intensified adherence counselling) to two historical com-
parison cohorts. Eligible patients were adult (C18 years)
HIV positive patients at Themba Lethu who were receiving
a second-line ART regimen containing lopinavir/ritonavir
or atazanavir/ritonavir and experienced a single elevated
viral load (C400 copies/ml) on second-line ART (Fig. 1).
Comparison cohorts: Comparison cohorts for the study
were chosen from an electronic patient medical record
database at the clinic. In order to compare patients who
received the intervention to patients who were managed
using other approaches, we included two comparison
cohorts from two different time periods prior to the use of
WisepillTM devices.
1. The first and historically earliest cohort called the
‘‘standard adherence cohort’’ included patients man-
aged according to the standard of care at the clinic
prior to the introduction of second-line clinic (between
July 2011 and July 2012). These patients received
routine re-adherence counselling with a counsellor or
social worker and the viral load was repeated 3 months
later. Genotyping and third-line drugs were not avail-
able during this period.
2. The second, called the ‘‘intensified adherence cohort’’
included patients enrolled in the second-line ART
clinic between July 2012 and the start of the interven-
tion period (August 2013). Since July 2012 Themba
Lethu has operated a second-line ART clinic focused
on managing patients who are at high risk of failing
second-line therapy (i.e., have an elevated viral
load C400 copies/ml while on second-line ART).
Patients are typically identified using an electronic
medical record called TherapyEdge-HIVTM. Patients
with high viral loads are flagged for enhanced adher-
ence counselling at their next clinic visit (1–2 months).
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The clinic manages these patients together during
normal clinic hours however these patients bypass
normal queues and undergo a longer intensified
adherence counselling session than normal with an
experienced counsellor or social worker. Patients then
meet with a senior clinician that same day to address
any adherence problems identified during counselling
and additional issues pertaining to treatment side
effects. Unlike the general clinic, attempts are made
for patients to be seen by the same clinician at
subsequent visits to maintain continuity and establish a
patient-provider relationship. The patient is advised to
continue their current regimen and return 3 months
later to retest whether their viral load is suppressed.
Patients that re-suppress (\400 copies/ml) their viral
load at this point return to the normal clinic flow
whereas those that fail to re-suppress are either sent for
HIV genotype testing if the clinician suspects drug
resistance or re-adherence counselling if the clinician
suspects that adherence has not improved. Both
resistance testing and third-line drugs (etraverine,
darunavir, raltegravir) were available at the site after
2012 through a PEPFAR grant.
Intervention cohort: In addition to intensified adherence
counselling (which was the standard of care at the time),
the intervention included the use of an EAMD until the first
follow-up viral load test (3-6 months after enrollment). The
intervention was designed to complement standard of care
at the clinic, with little disruption to clinic duties or flow
and apart from one additional study visit to coincide with
routine medical visits.
We piloted the intervention among eligible English
speaking patients enrolled in the second-line clinic between
13 August 2013 and 22 November 2013 with a single
recent (within the last 2 months) elevated viral load (C400
copies/ml). Patients also had to have a cell phone and be
willing to receive an SMS message of their choice if they
missed a scheduled dose. Intervention cohort patients were
identified and recruited from the second-line clinic. An
EAMD, otherwise referred to as a WisepillTM device, was
offered to any patient that met the study eligibility criteria
and provided informed consent.
The WisepillTM device is a portable rectangular box
(110 mm long 9 45 mm wide 9 12 mm deep) which
holds approximately 30 large or 60 small pills and contains
a cell phone SIM card, a 1100 mAH lithium polymer
rechargeable battery and a microchip to record time-date
stamp within the unit [17]. This wireless device has been
previously described [17]. The device monitors and records
each time it is opened and assuming that in most cases
when the device is opened medication is taken, the data it
records can be used as a proxy measure of treatment
adherence. In addition, the device can send data to a remote
web-based server via cell phone technology and send the
patient a reminder text message (SMS) whenever the
device has not been opened within a particular time win-
dow around the prescribed time for proper adherence.
Medical providers can also access online adherence records
and graphs. In addition to real-time medication adherence
monitoring, a signal (called a ‘‘heart beat’’) is periodically
sent to the device to determine if it is operating properly
and to determine battery and signal strength as well as
airtime available on the SIM card.
At enrollment (which coincided with intensified adher-
ence counselling) study staff recorded participant and
device information so that each participant could be linked
to their adherence data and clinical information. Partici-
pants returned to the clinic 1 month after enrollment where
study staff ensured proper use of the device (e.g., checked
battery, signal strength and airtime available). The clinician
also reviewed the adherence data collected and had a
focused discussion with the participant about their adher-
ence pattern. This additional visit was not part of the usual
standard of care that patients receive as part of the second-
Fig. 1 Schematic representation of the enrolment periods for the comparison and intervention cohorts. A summary of the visit schedule for the
intervention cohort is provided in the top right corner of the schematic
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line clinic. When participants returned for the follow-up
viral load test (3–6 months after enrollment) the device
was returned and the clinician reviewed the adherence data
with the patient. Finally, study staff administered a quali-
tative interview to determine the feasibility and accept-
ability of using the device. Questions addressed the
participants opinion of using the device, including ease or
difficulty of use; potential sigma and loss of confidentiality;
and how useful they thought the device was to monitor
adherence in real-time.
Study Variables
For the intervention cohort, the proportion achieving
adherence was calculated as the number of ‘‘recorded or
actual’’ doses divided by the number of ‘‘scheduled (as
prescribed)’’ doses. For this definition, ‘‘recorded’’ doses
occurred when the device was opened (morning or eve-
ning) within a 3 h window either side of the scheduled
time. If it occurred outside of this window period, the dose
was defined as ‘‘missed’’. Where multiple ‘‘recorded’’
doses were recorded in one period (morning or evening),
the dose closest to the scheduled dose was considered and
all other duplicates were disregarded. Required scheduled
dose was calculated as the total number of days multiplied
by the number of doses prescribed per day. The total
number of days from enrolment was determined as follows:
until study staff deactivated the device (definition 1), until
the last event recorded (definition 2), or until the repeat
viral load date (definition 3). We considered two cut-offs to
define good adherence; either taking at least 80 % (miss-
ing C20 %) or taking at least 95 % (missing C5 %) of the
prescribed medication [7].
All patient-level data, including information on demo-
graphics, medications, laboratory test results and other
clinical information were extracted from TherapyEdge-
HIVTM prior to the analysis. Viral load testing is not done
by the clinic, but by a central lab and therefore those
performing the viral load tests were blinded to the study
cohorts. Blood samples are sent to the National Health
Laboratory Service (NHLS) and viral load and CD4 count
results are uploaded directly into TherapyEdge-HIVTM
from the NHLS on a daily basis [24]. Because we
hypothesized that the device would also encourage patients
to remain in care, the primary study outcome was the
proportion of subjects in each group alive, in care and
virally suppressed by 6 months after eligibility (defined as
date of enrollment or adherence counselling for the inter-
vention and comparison cohorts respectively; typically
1–2 months after viral load C400 copies/ml on second-line
ART). Viral suppression was defined as a repeat viral
load\400 copies/ml. The repeat viral load was defined as
the first follow-up viral load (VL1) test 3 months after
eligibility. We allowed an additional 3 months to capture
patients that returned later for their medical visit. The study
team did not perform viral load testing and as such could
not ensure that all patients had a repeat viral load test.
Since retention in care was part of the outcome of interest,
this was accounted for in our primary outcome. For the
analysis, all patients without a repeat viral load by
6 months were considered failures (i.e., viral load C 400
copies/ml) [19].
In addition, we also estimated cumulative viral sup-
pression by 12 months. For patients who were alive in care,
not suppressed by 6 months (VL1), we followed patients
for an additional 6 months (VL2) to determine if they
could suppress by 12 months after eligibility.
Statistical Analysis
Continuous variables are described using medians with
corresponding interquartile ranges (IQR) and categorical
variables are expressed as simple proportions. For the
intervention cohort log-binomial regression was used to
estimate the association between poor adherence (defined
as either B 95 % or B 80 % [7] of required scheduled
dose) and unsuppressed virus (C400 copies/ml) between 3
and 6 months after enrolment.
The effect of the intervention on the primary outcome
(alive, in care and virally suppressed 6 months after single
elevated viral load on second-line), was estimated using
log-binomial regression. As the outcome was relatively
common (incidence of C10 %), we calculated relative
risks and corresponding 95 % confidence intervals (CI). In
addition, we conducted a secondary analysis restricted to
only patients with a repeat viral load. Models were adjusted
for gender, first elevated viral load, time to elevated viral
load and CD4 count at first elevated viral load. Loss to
follow-up (LTFU) was defined as being C3 months late for
the last scheduled visit with no subsequent visit. All-cause
mortality was ascertained through patient tracing and
linkage with the South African National Vital Registration
System for patients with a valid South African national
identification number (61 %) [24, 25].
Qualitative Analysis
At the final study visit, study staff administered a qualita-
tive interview consisting of a series of 13 open-ended
questions to all study participants (n = 49) to assess the
feasibility and acceptability of using the EAMD. Partici-
pant responses were captured on a paper case report form
and the raw data was transcribed and collated. Responses
were categorized and coded into key themes, and those
with similar content were summarized, with important
quotes noted as has been described by Kleiman [26].
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Qualitative interviews were read and general patterns or
themes were identified. We identified key points to help
refine the intervention approach and did not conduct a
formal analysis of the qualitative data.
Cost Per Patient Managed
We collected empirical data on the financial cost of the
intervention, incremental to the existing health services,
from the provider perspective, using ingredients based
methods. Therefore, we included costs of the device and
monitoring (e.g., cell phone airtime) for 6 months but
excluded staff time. Costs are presented in 2015 US dollars
(exchange rate 11.88). We calculated the cost per patient
managed assuming that resistance testing costs 300 US
dollars per patient and intensified adherence counselling
using WisepillTM EAMD costs 170 US dollars for
6 months. According to the 2015 South African National
consolidated guidelines for the management of HIV, adults
who have been on a PI containing regimen for at least a
year and have not achieved viral suppression would be
eligible for resistance testing to determine if third-line is
necessary [23]. Cost per patient managed was calculated as
the number of patients that did not suppress at 6 months
(i.e., would require a resistance test) multiplied by the cost
of the EAMD intervention and/or resistance testing divided
by the total number of patients in the cohort.
Compliance with Ethical Standards
All participants in the intervention cohort provided written
informed consent. Patient records/information for both
comparison cohorts was anonymized and de-identified
prior to analysis. Ethics clearance was approved by the
University of the Witwatersrand and Boston University
ethics committees.
Results
We enrolled 49 participants in the intervention cohort in
addition to 401 patients in the standard adherence cohort
and 314 in the intensified adherence cohort. The clinical
characteristics of the patients included are presented in
Table 1. Patients in the standard adherence cohort and
intensified adherence cohort were similar in terms of age at
eligibility, gender, first elevated viral load on second-line
ART, and time from start of second-line to first elevated
viral load. Compared to participants in the intervention
cohort, those who were in the standard adherence cohort
and intensified adherence cohort differed in terms of gen-
der (more females 70.6 and 72.0 % respectively vs.
59.2 %), had higher median CD4 counts at eligibility (417
and 353 respectively vs. 346 cells/mm3), and had a lower
median viral load at first elevated viral load on second-line
ART (1243 and 1508 respectively vs. 4804 copies/ml).
Evaluation of Adherence Devices Compared
to Intensified Adherence Counselling and Standard
Adherence Counselling
By 6 months after the first elevated viral load on second-
line ART, 44.9 % (22/49; 95 % CI 31.4–58.9) of partici-
pants from the WisepillTM intervention cohort, 38.5 %
(121/314; 95 % CI 33.3–44.0) from the intensified adher-
ence counselling cohort and 40.9 % (164/401; 95 % CI
36.1–45.7) from the standard adherence cohort were alive,
in care with a suppressed viral load below 400 copies/ml.
At the time of the analysis (close of dataset in November
2014), a total of 67.3, 69.4 and 77.8 % of patients in the
intervention, intensified adherence and standard adherence
cohort, respectively had re-suppressed their viral load
(Fig. 2).
When testing the association between the three groups
and our primary outcome we found that patients receiving
a combination of EAMD and intensified adherence
counselling demonstrated small differences in proportions
alive, in care and virally suppressed at 6 months after an
elevated viral load on second-line ART when compared to
intensified adherence counselling (RR 1.19; 95 % CI
0.85–1.67; risk difference 0.06) or adherence counselling
alone (RR 1.12; 95 % CI 0.81–1.56; risk difference 0.04).
After adjusting for gender, first elevated viral load, time to
elevated viral load and CD4 count at first elevated viral
load, we saw no difference in the primary outcome for the
different approaches to managing care (Table 2). Viral
load suppression was also similar between the comparison
cohorts (intensified adherence counselling vs. adherence
counselling alone RR 1.04; 95 % CI 0.92–1.17), with a
narrower confidence interval. When we restricted the
analysis to patients with a repeat viral load, the proportion
alive, in care and virally suppressed at 6 months increased
from 44.9 to 45.8 % in intervention cohort, from 38.5 to
57.6 % in the intensified adherence cohort and from 40.9
to 55.6 % in the standard adherence counselling cohort.
Based on our results, we conducted a sensitivity analysis,
and assumed that 50 % of those with a missing viral load
(initially assumed they were all failures) were alive, in
care and virally suppressed at 6 months. When compared
to intensified adherence counselling (RR 0.81; 95 % CI
0.58–1.13) or adherence counselling alone (RR 0.83;
95 % CI 0.60–1.15), the intervention cohort was less
likely to achieve the primary outcome, demonstrating the
variability in results due to informative missingness of
viral load data.
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Cost Analysis
If we consider that 61.5 % of the total intensified adherence
cohort (n = 314) would require resistance testing after
6 months then the cost per patient managed would be 184
US dollars (193 9 300 US dollars 7 314). If one imple-
mented the EAMD intervention then theoretically the
proportion requiring resistance testing would drop from
61.5 to 55.1 % (see Table 2—difference in the proportion
alive, in care and virally suppressed at 6 months) but the
cost per patient managed would increase to 335 US dollars
(173 9 470 US dollars [$300 for resistance testing ?$170
for Wisepill monitoring] plus 141 9 170 US
dollars 7 314).
Intervention Participants and Adherence Levels
Intervention cohort participants used the devices for a
median of 4.9 months (IQR 4.2–5.1). The majority
(85.7 %) were on a standard second-line regimen of
lamivudine (3TC) and LPVr with various non-nucleoside
reverse transcriptase inhibitors (stavudine 26.5 %; teno-
fovir 34.7 %; zidovudine 38.8 %) at study enrolment. The
majority (92 %; n = 45) of participants took ART twice
Table 1 Patient demographic and clinical characteristics at eligibility and treatment outcomes for each cohort included at Themba Lethu HIV
clinic in Johannesburg, South Africa
Characteristics of patients at the first elevated viral load on
second-line ART
WisepillTM intervention
cohort (n = 49)
Intensified adherence
cohort (n = 314)
Standard adherence
cohort (n = 401)
Gender, female, n (%) 29 (59.2 %) 226 (72.0 %) 283 (70.6 %)
Age, years, median (IQR) 37.6 (33.6–45.3) 35.2 (30.5–40.9) 35.2 (30.3–41.2)
CD4 cells/mm3, median (IQR) 346 (166–403) 353 (189–558) 417 (260–609)
\ 50 1/37 (2.7 %) 11/188 (5.9 %) 16/393 (4.0 %)
51–100 4/37 (10.8 %) 8/188 (4.3 %) 9/393 (2.3 %)
101–250 8/37 (21.6 %) 48/188 (25.5 %) 65/393 (16.5 %)
C 250a 24/37 (64.9 %) 121/188 (64.4 %) 303/393 (77.1 %)
Time on ART prior to study eligibility (elevated viral load on
second-line), months, median (IQR)
48.8 (30.4–68.8) 35.4 (20.1–60.6) 37.6 (21.4–63.5)
Time from start of second-line to study eligibility, months,
median (IQR)
11.5 (5.0–23.4) 11.8 (5.1–26.2) 14.8 (6.0–31.2)
Viral load at study eligibility, copies/ml, median (IQR) 4804 (1505–22,455) 1508 (690–15,000) 1243 (648–4461)
Second-line ART regimen, n (%)
ABC_3TC_ LPVr 0 6/314 (1.9 %) 9/401 (2.2 %)
TDF_3TC_ LPVr 17/49 (34.7 %) 74/314 (23.6 %) 143/401 (35.7 %)
AZT_3TC_LPVr 12/49 (24.5 %) 71/314 (22.6 %) 81/401 (20.2 %)
AZT_ddI_LPVr 7/49 (14.3 %) 68/314 (21.7 %) 41/401 (10.2 %)
d4T_3TC_LPVr 13/49 (26.5 %) 95/314 (30.3 %) 127/401 (31.7 %)
Primary outcome at 6 months
Alive, in care, suppressed, n (%) 22/49 (44.9 %) 121/314 (38.5 %) 164/401 (40.9 %)
Alive in care, not suppressed, n (%) 26/49 (53.1 %) 170/314 (54.1 %) 232/401 (59.1 %)
Missing viral loads 0 81 101
Not in care 1/49 (0.3 %) 23/314 (7.3 %) 5/401 (1.3 %)
Dead 0 5 1
Loss to follow-up 1 18 4
Final outcome by 12 months
Alive, in care, suppressed, n (%) 33/49 (67.3 %) 218/314 (69.4 %) 312/401 (77.8 %)
Alive in care, not suppressed, n (%) 15/49 (30.6 %) 73/314 (23.2 %) 80/401 (20.0 %)
Missing viral load 1 40 20
Not in care 1/49 (0.3 %) 23/314 (7.3 %) 9/401 (2.2 %)
Dead 0 5 1
Loss to follow-up 1 18 8
ABC, abacavir; 3TC lamivudine; LPVr, lopinavir ritonavir; TDF, tenofovir; AZT, zidovudine; ddI, didanosine; d4T, stavudine
a Loss to follow-up defined as missing their last scheduled visit C3 months
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daily while the remaining 8 % took a once daily regimen.
The median time on ART was 6.1 years (IQR 3.7–7.7) at
enrolment into the study. Median cumulative adherence
among intervention participants was 90.7 % (IQR
79.2–96.2), 85.4 % (IQR 68.7–96.8) and 86.7 % (IQR
68.6–95.4) for definition 1, 2 and 3 respectively. We
describe the study population, stratified by adherence cal-
culated from enrolment until last event recorded (definition
2) (Table 3). Overall, 63 % of all participants enrolled in
the study (59 % of females and 70 % of males) took more
than 80 % while only 27 % (13/49) took more than 95 %
of their prescribed medication. The proportion of patients
taking[80 % of doses dropped from 76 % at 1 month
post-enrolment to 53 and 49 % at 2 and 3 months
respectively.
By the date of dataset closure (November 2014; allow-
ing a minimal of 12 months of follow-up), 48 (98 %)
patients had a repeat viral load while one patient was lost to
follow-up and had no repeat viral load. Of those with a
repeat viral load, 46 % (95 % CI 32–60; 22/48) were
Fig. 2 Viral suppression at 6 (VL1) and 12 (VL2) months among
patients on second-line ART with an elevated viral load who were
enrolled to receive electronic patient adherence monitoring (Wise-
pillTM Intervention cohort) and comparison cohorts; those receiving
intensified adherence counselling or adherence counselling alone
(standard adherence cohort). (LTFU; C3 months late for the last
scheduled visit with no subsequent visit)
Table 2 Association between adherence intervention and being alive, in care and virally suppressed at 6 months
n, % Alive, in care and virally suppressed
Crude RR (95 % CI) Adjusted RRa (95 % CI)
Full analysisb
Intensified adherence counselling 121/314 (38.5 %) 1.0 1.0
WisepillTM electronic adherence monitoring 22/49 (44.9 %) 1.19 (0.85–1.67) 1.17 (0.83–1.66)
Standard adherence counselling 164/401 (40.9 %) 1.0 1.0
WisepillTM electronic adherence monitoring 22/49 (44.9 %) 1.12 (0.81–1.56) 1.06 (0.75–1.49)
Restricted analysis among those with a viral load
Intensified adherence counselling 121/210 (57.6 %) 1.0 1.0
WisepillTM electronic adherence monitoring 22/48 (45.8 %) 0.80 (0.57–1.11) 0.79 (0.56–1.10)
Standard adherence counselling 164/295 (55.6 %) 1.0 1.0
WisepillTM electronic adherence monitoring 22/48 (45.8 %) 0.82 (0.60–1.14) 0.74 (0.53–1.03)
RR relative risk, CI confidence interval
a Model adjusted for gender, first elevated viral load, time to elevated viral load and CD4 count at first elevated viral load
b For the full analysis, all patients without a repeat viral load by 6 months were considered failures (i.e. viral load C400 copies/ml)
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undetectable (\400 copies/ml) while 29 % (95 % CI
18–43; 14/48) were between 400 and 1000 copies/ml and
25 % (95 % CI 14–39; 12/48) were greater than 1000
copies/ml. For the primary outcome analysis we considered
the one lost patient to be a failure as they did not have a
repeat viral load.
Compared to those with good adherence ([80 %), par-
ticipants with poor adherence (B80 %) had a higher risk
for a follow up viral load C400 copies/ml [relative risk
(RR) 1.47 95 % CI 0.97–2.23]. Using different definitions
of adherence (Table 4), patients with poor adherence were
more likely to have a repeat viral load C400 copies/ml,
although the estimate lacked precision due to our small
sample size.
Among the 49 intervention cohort subjects, 10,332
events (i.e., device openings) were recorded. No partici-
pant’s device had a signal at any point indicative that it
could not pick up a signal or communicate with the server.
A small number (13.1 %) of the drug intakes had a signal
strength below 10 (but any signal strength value is regarded
as adequate) and 10.8 % of all drug intakes had a battery
strength less than 3700 mV suggesting that the battery was
low and needed recharging. Drug intakes were however
still recorded even when the battery voltage dropped to the
lowest at 3400 mV.
Acceptability
We report good uptake of the device with only two patients
who were offered it refusing to participate. Overall, 96 %
of participants reported that WisepillTM helped them to
remember to take their medication. Most patients did not
have a problem telling people what the device was when
asked, one participant said he just told people it was a
‘‘machine that helps me remember to take my medication’’.
Participants reported that the device was ‘‘easy to carry
Table 3 Characteristics of patients on second-line ART with an elevated viral load and enrolled to receive electronic patient adherence
monitoring, stratified by adherence calculated from enrolment until last event recorded (definition 2) (n = 49)
Characteristic Adherence[ 80 %
(n = 31)
Adherence B 80 %
(n = 18)
Gender, female, n (%) 17/29 (58.6 %) 12/29 (41.4 %)
Age, years, median (IQR) 42.9 (36.2–50.7) 39.2 (38.1–44.5)
Education—secondary level and beyond, n (%) 21/35 (60.0 %) 14/35 (40.0 %)
Employed, n (%) 21/35 (60.0 %) 14/35 (40.0 %)
First-line ART regimen, n (%)
d4T_3TC_EFV 24/36 (66.7 %) 12/36 (33.3 %)
TDF_3TC_EFV 2/4 (50.0 %) 2/4 (50.0 %)
AZT_3TC_EFV 2/3 (66.7 %) 1/3 (33.3 %)
Other 3/6 (9.6 %) 3/6 (50.0 %)
Time on first-line ART, median (IQR) 6.2 (3.4–7.8) 5.7 (3.7–7.4)
Second-line ART regimen, n (%)
TDF_3TC _LPVr 11/17 (64.7 %) 6/17 (35.3 %)
AZT_3TC_LPVr 10/12 (83.3 %) 2/12 (16.7 %)
AZT_ddI _LPVr 4/7 (57.1 %) 3/7 (42.9 %)
d4T_3TC_LPVr 6/13 (46.2 %) 7/13 (53.8 %)
Time from second-line initiation to eligibility (i.e. elevated viral load), median months
(IQR)
9.8 (4.1–21.8) 18.4 (6.2–30.5)
CD4 cells/mm3 at eligibility, median (IQR) 367 (173–568) 373 (168–413)
\250 8/12 (66.7 %) 4/12 (33.3 %)
C250 14/24 (58.3 %) 10/24 (41.7 %)
Missing 9/13 (69.2 %) 4/13 (30.8 %)
Follow up viral load (3–6 months after eligibility) 280 (100–781) 601 (198–1500)
\400 copies/ml 16/22 (72.7 %) 6/22 (27.3 %)
400–1000 copies/ml 9/14 (64.3 %) 5/14 (35.7 %)
1000–10,000 copies/ml 5/9 (55.6 %) 4/9 (44.4 %)
C10,000 copies/ml 1/3 (33.3 %) 2/3 (77.7 %)
Missing 0/1 (0 %) 1/1 (100.0 %)
ABC, abacavir; 3TC, lamivudine; LPVr, lopinavir ritonavir; TDF, tenofovir; AZT, zidovudine; ddI, didanosine; d4T, stavudine
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around’’, ‘‘it’s portable’’, ‘‘I can keep all my tablets in one
place’’, ‘‘it reminds me to take my medication on time’’,
‘‘looks like a modern day gadget’’, ‘‘better than carrying
packets of pills’’ and ‘‘it is a good box’’. Participants felt
that the device not only reminded them to take their pills
when they forgot but it helped them to be more careful and
responsible about taking their pills because they knew that
someone was ‘‘watching’’ or monitoring them. On the
negative side participants reported that ‘‘it would send
reminders even when I took my medication’’, ‘‘I didn’t like
that it had to be charged’’, ‘‘it is too big’’, ‘‘people asked
about the box’’ and ‘‘timing of SMS was inconvenient’’.
Participants suggested that the device should be com-
bined with a reminder (e.g., alarm, buzzer etc.), preferably
in one device. Participants also reported that there should
not be long delays between forgetting to take their medi-
cation and receiving a SMS reminder. Some patients also
complained about getting multiple reminders despite
actually taking their medication. Participants also men-
tioned that the device could be smaller and that it should be
designed to fit into trouser pockets for convenience, espe-
cially in men.
Overall, participants were optimistic about the device
and their responses indicated that they found the device
‘‘acceptable and useful’’. One participant reported that ‘‘It
was great to be reminded to take my medication’’ while
another participant mentioned that ‘‘This box is very pre-
cious, it is a nice box. I don’t have to be reminded by my
wife. I wish I can keep it’’.
Discussion
We conducted a pilot study in Johannesburg, South Africa
to determine if short-term use of electronic patient adher-
ence monitoring devices can improve adherence in patients
failing second-line antiretroviral therapy. By 6 months
after eligibility, 44.9 % (95 % CI 31.4–58.9) of partici-
pants in the intervention cohort re-suppressed their virus
without a regimen switch. This is similar to what has been
reported for re-suppression on first-line ART in South
Africa (40 %) [27]. A significant proportion of patients had
virologic failure despite good adherence, highlighting those
most likely to benefit from resistance testing and third-line
drugs.
Despite the fact that participants found the device ‘‘ac-
ceptable and useful’’, WisepillTM resulted in modest
improvement in the primary outcome over intensified
adherence counselling. We demonstrate that compared to
those who received intensified adherence counselling,
patients receiving combination intervention of electronic
adherence monitoring and intensified adherence coun-
selling were slightly more likely to be alive, in care and
virally suppressed at 6 months after an elevated viral load
on second-line ART (44.9 vs. 38.5 %), for an additional
cost of 151 US dollars per patient managed. In order for the
intervention to be considered, either the effectiveness
would have to be improved ([95 % alive, in care and
virally suppressed) or the cost of the intervention would
have to be dramatically reduced (\18 US dollars). We
Table 4 Association between
poor adherence (B80 or 95 %)
and a repeat viral load C400
copies/ml in the intervention
group
Viral load C 400 copies/ml n % Crude RR (95 % CI) Adjusted RRa (95 % CI)
Definition 1
Adherence[ 80 % 17/35 (48.6 %) 1.0 1.0
Adherence B 80 % 10/14 (71.4 %) 1.47 (0.91–2.37) 1.47 (0.97–2.23)
Adherence[ 95 % 8/14 (57.1 %) 1.0 1.0
Adherence B 95 % 19/35 (54.3 %) 0.95 (0.55–1.64) 1.06 (0.63–1.78)
Definition 2
Adherence[ 80 % 15/31 (48.4 %) 1.0 1.0
Adherence B 80 % 12/18 (66.7 %) 1.38 (0.85–2.25) 1.35 (0.86–2.12)
Adherence[ 95 % 7/13 (53.9 %) 1.0 1.0
Adherence B 95 % 20/36 (55.6 %) 1.03 (0.58–1.85) 1.15 (0.66–2.0)
Definition 3
Adherence[ 80 % 16/33 (48.5 %) 1.0 1.0
Adherence B 80 % 11/16 (68.8 %) 1.42 (0.88–2.30) 1.48 (0.98–2.24)
Adherence[ 95 % 7/13 (53.9 %) 1.0 1.0
Adherence B 95 % 20/36 (55.6 %) 1.03 (0.58–1.85) 1.15 (0.66–2.0)
a Model adjusted for time to elevated viral load calculated from start of second-line ART until first elevated
viral load. The total number of days was determined as follows: from enrolment until study staff deacti-
vated the device (definition 1), from enrolment to last event recorded (definition 2), or until the repeat viral
load date (definition 3)
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could not demonstrate that EAMD could significantly
improve long-term adherence, as measured by viral sup-
pression, but the results are encouraging since patients that
re-suppress early are more likely to remain virally sup-
pressed [28]. Our findings are similar to those recently
reported from a randomized controlled trial among patients
on first-line ART [19]. Viral suppression may not be the
most appropriate way to measure the effectiveness of
EAMD and other outcomes such as treatment interruptions,
missed clinic visits and long term viral suppression may be
more suitable.
Overall re-suppression rates were low but expected
given the study population. A recent study among patients
experiencing treatment failure on protease-inhibitor based
second-line ART showed that 46 % (51/111) of patients
reach re-suppression at first follow-up viral load after an
adherence support intervention similar to the intensified
adherence cohort described here [28]. Others have also
reported that that 46 % of patients experiencing failure on
second-line ART achieve viral re-suppression within
3 months, 18 % within 6 months and 5 % within 9 months
of a second-line failure intervention lasting 3 months [29].
The encouraging news is that patients that re-suppress early
(e.g., at the first follow-up viral load) are three times more
likely to remain virally suppressed, compared to those that
reach viral suppression later. An additional 41 % of
patients reach viral re-suppression at the second or third
follow-up viral load test [28]. This suggests that longer
follow-up, beyond 6 months, may be needed in order to
accurately determine the impact of adherence
interventions.
Virological failure may be caused by a number of fac-
tors, including drug resistance, length of time on treatment
and poor adherence [28, 30]. We demonstrate that partic-
ipants with poor adherence (B80 %) had a higher risk for a
follow-up viral load C400 copies/ml (71.4 vs. 48.6 %). In
a study by Shuter and colleagues, 80 % of LPVr recipients
achieved an undetectable viral load (\400 copies/ml)
despite a mean adherence rate of 73 % and substantial
ART experience [31, 32]. LPVr’s forgiveness of non-ad-
herence is likely attributable to two separate factors; first is
its pharmacokinetic profile, which exceeds 50 % effective
concentration for more than 24 h in normal volunteers, so
patients without resistant virus can miss one of two daily
doses but still maintain therapeutic levels of the drug
between doses and, second, is the low frequency at which
the virus develops resistance to this agent [32].
We also report that adherence dropped at 2 and
3 months post-enrolment. Recent evidence from this cohort
has revealed social and behavioural factors including use of
herbal/traditional medicine, alcohol and depression were
significantly associated with failure to re-suppress viral
load on second-line ART following intensified adherence
counselling (results not shown). Therefore, interventions to
address these barriers should be considered as part of the
adherence intervention package to improve adherence over
time [33, 34].
Limitations
Our findings should be considered in light of the study
limitations. Firstly, compared to those in the WisepillTM
intervention cohort, the intensified adherence cohort and
standard adherence cohort had a considerable amount of
missing viral load data (25.8 and 25.2 % by 6 months and
12.7 and 5.0 % by 12 months). Patients with missing viral
loads were considered failures [19], potentially leading to
an overestimation of the effect of the WisepillTM inter-
vention. To address this we included a sensitivity analysis
to determine the potential impact if a proportion of those
with missing viral loads (50 %) had suppressed their viral
load.
Second, we could not confirm adequate cellular signal at
the participants’ home or work prior to enrolment in the
study [17]. We did not have approval to contact partici-
pants (e.g., telephonically or through home visits) if there
was a lapse in signal and could therefore not determine if
the cause was technical failure (e.g., low battery power or
low airtime) or behavioural (e.g., opting not to use the
device). However, to minimize this during the study, par-
ticipants were sent an SMS reminder to recharge the bat-
tery when low battery power was detected. Other factors
including signal strength and issues with cell phones (e.g.,
lost, left at home etc.) could have resulted in more patients
being classified as poorly adherent. Better cell-phone
coverage would reduce delays in transmissions, possibly
improving the effectiveness of the intervention.
Third, this study was not a randomized controlled trial
aimed at measuring the effect of the intervention but rather
a pilot study to generate preliminary estimates of effec-
tiveness, generate preliminary cost data and evaluate the
feasibility of EAMD. The pre-post design may result in
secular trends or periodic variation. Study enrolment took
place near the holiday period which may have resulted in a
longer duration between counselling and the repeat viral
load for some. To overcome this we used the first repeat
viral load within 6 months of eligibility. Furthermore,
some participants travelled out of South Africa and cell
phone coverage did not include international roaming.
These patients would have recorded missed drug scheduled
doses in their adherence pattern and also would not have
received SMS reminders when low battery was detected.
Participation in a study may in itself motivate adher-
ence. Patient motivation can be enhanced by free accessi-
ble care, approachable and supportive healthcare workers,
broad social acceptance of ART, and past first-hand
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experiences with AIDS-related co-morbidity and mortality
[35]. Although we did not conduct a formal analysis of the
qualitative data, EAMD have been shown to be feasible in
similar settings [36]. Although EAMD allows for moni-
toring and optimizing adherence in real-time (e.g., with the
SMS reminders), we limited patient interaction to clinic
visits, when it may have already be too late for some
patients to prevent failure or drug resistance. Also,
important to note is that opening the device does not nec-
essarily translate into participants taking the drugs cor-
rectly, and this intervention is dependent on the patient
using the device correctly. These are important factors that
should be considered when implementing adherence
reminder devices in routine settings, emphasising the
importance of context, examining specific features of the
intervention and rigorous evaluation of implementation
impact and performance [14, 15].
Last, we restricted the intervention period to 3 months.
It may be important to consider a longer intervention per-
iod (±6–9 months) for patients on second-line ART as
adopted in other studies [37, 38]. Murphy and colleagues
also report that time to virologic suppression is most rapid
among patients with 91–100 % adherence, so those
with B80 % adherence may take longer to reach virologic
suppression [38].
Conclusion
Adherence strategies increase the durability of second-line
ART, decrease the need for costly third-line regimens and
prevent unnecessary genotyping tests [28]. Our findings are
important since few studies have investigated adherence
interventions among patients failing second-line ART. In
addition, this is one of the first studies to investigate the use
of EAMD in a second-line ART population, the population
where it could be cost-effective at current prices. Results
are encouraging especially since patients that re-suppress at
first follow-up viral load are more likely to remain virally
suppressed [28]. Finally, adherence is associated with
virological outcomes; a mere 10 % improvement in the rate
of adherence has been shown to double the chance of
achieving an undetectable viral load and reduce the risk of
virological failure by as much as 73 % [4, 38].
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